FDA Rejects 510(k) Exemption Petition for Radiology Computer-Aided Diagnostic Devices in 2026; Review Requirements Remain Unchanged

Published: September 30, 2026, 15:26 | Category: Registration and Market Access

Event and Original Order

On September 17, 2026, the U.S. Food and Drug Administration (FDA) published in the Federal Register a final order titled 'Medical Devices; Exemption From Premarket Notification; Radiology Computer-Aided Detection and/or Diagnosis Devices and Computer-Aided Triage and Notification Devices.' The order makes a final determination on a prior petition and became effective on September 17, 2026.

Petition and Decision

The notice of acceptance of the petition was published in the Federal Register on December 29, 2025. The petitioner requested that, subject to the conditions described, several generic device types be exempted from premarket notification (510(k)) requirements. The types involved included: radiology computer-aided diagnostic software for suspicious cancerous lesions; medical image analyzers; radiology computer-aided triage and notification software; and radiology computer-aided detection and diagnosis software.

In its response to the petitioner dated April 1, 2026, FDA denied the petition. FDA stated that, in considering the petition and docket comments, it assumed that all elements of the petitioner's proposal were 'partial limitations on exemptions' that it could consider under section 510(m)(2) of the Federal Food, Drug, and Cosmetic Act, and expressed them collectively in the order on that basis.

Practical Impact

Because the petition was denied, the above device types did not receive exemption from premarket notification and remain subject to 510(k) review under current requirements. For companies, this means that for the U.S. market pathway for such radiology software, 510(k) remains the default route; this order does not create a compliance space for avoiding submission.

Scope and Boundaries

This order addresses the generic device types covered by the petition, not a specific registration conclusion for any one company or product. The effect of the order is to determine whether an exemption is established; it does not change the classification rules themselves or add new performance standards. Whether a specific product falls within these types and which submission pathway should be adopted still requires case-by-case judgment based on intended use, risk, and FDA's current classification requirements.

Key Dates

• December 29, 2025: petition notice published in the Federal Register.
• April 1, 2026: FDA denied the petition.
• September 17, 2026: final order published and effective.

Companies planning or continuing U.S. submission plans for relevant products should rely on this order and current FDA guidance as the latest basis.

Sources and Applicability

Source: U.S. Food and Drug Administration (FDA), Federal Register final order, 'Medical Devices; Exemption From Premarket Notification; Radiology Computer-Aided Detection and/or Diagnosis Devices and Computer-Aided Triage and Notification Devices,' published and effective September 17, 2026.

https://www.federalregister.gov/documents/2026/09/17/2026-19074/medical-devices-exemption-from-premarket-notification-radiology-computer-aided-detection-andor

U.S. Government Publishing Office, Federal Register original PDF (Vol. 91): https://www.govinfo.gov/content/pkg/FR-2026-09-17/pdf/2026-19074.pdf

Verification scope and access date: This review verified the above Federal Register order page and the Government Publishing Office original PDF text. The access date was September 30, 2026. The petition notice date, denial date, and effective date of the order are taken from the above original text.

Applicability note: This article is an interpretation of public regulatory information and does not constitute a conclusion or commitment for any specific product, company, or registration application. The official original text prevails; information may change with subsequent official updates.

Information Sources

• U.S. Food and Drug Administration (FDA) — Federal Register final order 2026-09-17
• U.S. Government Publishing Office — Federal Register PDF (Vol. 91)

AIMEILI Regulatory Interpretation and Business Impact

Regulatory interpretation: The final order confirms that FDA has not created a 510(k) exemption for radiology computer-aided detection and/or diagnosis devices or computer-aided triage and notification devices. FDA followed the section 510(m) process, considered the proposed conditions as partial limitations, and denied the petition. The decision does not reclassify the devices or impose new special controls; it preserves the existing premarket notification requirement.

Business impact: Manufacturers, distributors, CROs, and regulatory affairs teams should continue to treat 510(k) as the default U.S. pathway for these device types. Product development, clinical evaluation, human factors, software lifecycle, and cybersecurity documentation should be aligned with 510(k) expectations. Market launch timelines should not assume an exemption. If a product's intended use, indications, or risk profile place it outside the petition's generic device types, a separate regulatory assessment is needed. Companies with pending or planned submissions should document the order in their regulatory strategy and monitor FDA guidance for any future changes.

Recommended actions:

• Confirm whether the product meets the definitions of radiology computer-aided detection and/or diagnosis devices or computer-aided triage and notification devices.
• Maintain a 510(k) strategy, including predicate identification, performance testing, software documentation, and cybersecurity information.
• Review labeling and intended use to avoid unnecessary broadening that could affect the submission pathway.
• Record the key dates and the Federal Register order in the regulatory intelligence file.
• Consult FDA guidance and, if needed, seek pre-submission feedback for novel features.

AIMEILI view: The order removes uncertainty about a possible exemption for these device types. For global manufacturers, the U.S. market entry requirement remains a 510(k), so early regulatory planning and documentation quality are critical. Companies should not delay submission preparation based on the petition.